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Abstract The focal adhesion protein VASP, a possible link be- 
tween signal transduction pathways and the microfilament sys- 
tem, is phosphorylated by both cAMP- and cGMP-dependent 
protein kinases in vitro and in intact cells. Here, the analysis of 
VASP dephosphorylation by the serinelthreonine protein 
phosphatases (PP) PPI, PP2A, PP2B and PP2C in vitro is 
reported. The phosphatases differed in their selectivity with re- 
spect to the dephosphorylation of individual VASP phosphoryla- 
tion sites. Incubation of human platelets with okadaic acid, a 
potent inhibitor of PPI and PP2A, caused the accumulation of 
phosphorylated VASP indicating that the phosphorylation status 
of VASP in intact cells is regulated to a major extent by serine! 
threonine protein phosphatases. Furthermore, the accumulation 
of phosphorylated cAMP-dependent protein kinase substrate(s) 
appears to account for inhibitory effects of okadaic acid on plate- 
let function. 
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I. Introduction 
Platelet function is regulated by a number of vasoactive 
agents. Whereas agonists like thrombin, thromboxane A2 and 
ADP activate platelets resulting in shape change, adhesion, 
aggregation and degranulation [1], platelets are inhibited by 
cAMP- and cGMP-elevating agents uch as prostaglandins E l
and I2 or nitrovasodilators [2,3]. The 46/50 kDa focal adhesion 
and microfilament associated [4] vasodilator-stimulated 
phosphoprotein (VASP) is a common substrate of cAMP-de- 
pendent and cGMP-dependent protein kinases (cAK, cGK) not 
only in human platelets but also in a variety of other cell types 
[4-9]. VASP phosphorylation correlates very well with the inhi- 
bition of platelet aggregation [2,6,8] and in particular with the 
inhibition of fibrinogen binding to glycoprotein I Ib-I I Ia [10]. 
Recent data suggest hat VASP is an important link between 
signal transduction pathways and the microfilament system 
[11,12]. 
Three cAK/cGK VASP phosphorylation sites have been 
identified (Ser 157, Ser 239, Thr 27s) [13,14]. All three sites are used 
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by both protein kinases, but with different priority. In vitro, 
Ser 239 is the phosphorylation site preferred by cGK while cAK 
first phosphorylates Ser 157. Phosphorylation f Ser 157 causes the 
phosphorylation-induced mobility shift of VASP in SDS- 
PAGE from 46 kDa to 50 kDa. Consequently, transient phos- 
phorylation of the 46 kDa VASP species is observed only with 
cGK but not with cAK [8,13]. 
The phosphorylation state of proteins is not only regulated 
by protein kinases but also by protein phosphatases (PP). In 
platelets, several different protein phosphatases have been iden- 
tified, namely protein serine/threonine phosphatases type 1, 
type 2A [15,16], type 2B [17,18] as well as protein tyrosine 
phosphatases [19]. 
Studies with the potent and specific serine/threonine protein 
phosphatase inhibitors okadaic acid, calyculin A and tautomy- 
cin [20,21] demonstrated that these phosphatase inhibitors af- 
fect platelet function. All three phosphatase inhibitors reduced 
the receptor-mediated Ca2+-influx into human platelets [22]. 
Earlier, okadaic acid was shown to inhibit platelet aggregation 
and other events associated with thrombin-induced platelet ac- 
tivation [15,23,24]. Also, effects on protein phosphorylation 
after treatment of cells with okadaic acid or calyculin A have 
been observed [15,23,25,26]. However, the identities of most 
phosphoproteins, affected by individual protein phosphatases 
and/or phosphatase inhibitors, are still unclear. Therefore, the 
identification of endogenous serine/threonine phosphatase ub- 
strates is mandatory in order to dissect he physiological func- 
tions of the different serine/threonine protein phosphatases. 
In this study, we investigated the dephosphorylation f the 
well characterized cyclic nucleotide-dependent protein kinase 
substrate VASP by serine/threonine protein phosphatases in
vitro and in intact human platelets. A preliminary account of 
this work has been presented in abstract form [27]. 
2. Materials and methods 
2.1. Protein purification 
The catalytic subunits of PP1 and PP2A from rabbit skeletal muscle, 
PP2B from bovine brain and PP2C from rat liver were purified as 
described [28]. Catalytic subunit of cAK, cGK and VASP were purified 
essentially as described [7], with some modifications as indicated [4]. 
2.2. Phosphorylation of purified VASP 
VASP (2.9 pM) was incubated for 30 min at 30°C in buffer A (50 
mM Tris-HCl pH 7.2, 1 mM dithioerythritol, 5 mM MgCI2, 0.01% 
bovine serum albumin) containing 100 /2M [~,-3ZP]ATP (44,4 GBq/ 
mmol; Amersham Buchler, Braunschweig, Germany) and 150 nM of 
cAK catalytic subunit. Under these conditions about 2-3 mole of phos- 
phate per mole of VASP are incorporated [7,29]. 32p-phosphorylated 
YASP was separated by one- or two-dimensional gel electrophoresis 
and detected by autoradiography. Autophosphorylation f cAK or 
cGK does not interfere with the analysis of VASP phosphorylation [7]. 
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2.3. Dephosphorylation of purified VASP 
Following the phosphorylation of VASE the catalytic subunit of 
cAK was inhibited by 10 ¢tM PKI-peptide (TTYADFIASGRTGRR- 
NAIHD; [30]). Traces of PBS (from purified VASP) which inhibit the 
phosphatases were removed by centrifugation through a MicroSpin 
S-200 HR column (Pharmacia, Freiburg, Germany), pre-equilibrated 
with buffer B (buffer A containing 0.03% (w/v) Nonidet P40). 
Phosphorylated VASP (2.3 pM) was incubated at 30°C in buffer B 
(which also contained 0.05 mg/ml calmodulin/0.5 mM CaCI2 for PP2B 
or 20 mM MgC12 for PP2C) with 0.34).5 ¢tM of the respective phos- 
phatase. At the time points indicated, aliquots were removed and the 
reaction was terminated by the addition of an SDS stop solution (for 
SDS-PAGE analysis) or by the addition of lysis buffer (9 M urea, 2% 
(w/v) Nonidet P40, 2% (v/v) 2-mercaptoethanol, 0.8% (w/v) ampholines 
pH 3-10) (for two-dimensional gel electrophoresis). 
2.4. Incubation of washed platelets with okadaic acid, Sp-5,6-DCI- 
cBiMPS and lloprost 
For the preparation of washed human platelets, venous blood from 
healthy volunteers was collected into citrate buffer (20 mM sodium 
citrate, 3 mM EDTA pH 5.5) and centrifuged (300 × g for 10 rain). 
Platelets of the resulting supernatant (platelet rich plasma) were pel- 
leted at 420 x g for 20 min and resuspended in modified Tyrode's buffer 
(10 mM HEPES pH 7.4, 2.7 mM KC1, 137 mM NaC1, 5 mM glucose, 
1 mM EDTA). This step was repeated once, and platelets were resus- 
pended at a concentration f 1 x 10 9 cells/ml. After a 30 min preincuba- 
tion at 20°C, platelet aliquots were incubated with different concentra- 
tions of okadaic acid (ammonium salt; LC Laboratories) for 40 min at 
37°C. After this incubation, platelets were rapidly pelleted by centrifu- 
gation at 8,200 x g for 10 s, and the pellet was resuspended in lysis 
buffer for two-dimensional gel electrophoresis. In other experiments, 
washed platelets were similarly incubated with 5 nM Iloprost (a stable 
analogue of prostaglandin lz; kind gift of Schering, Berlin, Germany) 
or 0.2 mM Sp-5,6-DCI-cBiMPS (Sp-5,6-dichloro-l-fl-o-ribofurano- 
sylbenzimidazole-Y,5'-monophosphorothioate; a membrane per- 
meable cAMP-analogue; Biolog, Bremen, Germany). 
2.5. Immunoblotting 
Immunoblotting was done as described [4], except hat antibodies 
bound to immobilized 32P-labeled VASP were detected by the enhanced 
chemiluminescence (ECL) detection method (Amersham Buchler, 
Braunschweig, Germany). 
2.6. Two-dimensional gel electrophoresis 
For isoelectric focusing, Immobiline dry strips pH 3-10.5 (Pharma- 
cia, Freiburg, Germany) were pre-swollen overnight in rehydratization- 
solution (8 M urea, 0.5% (w/v) Nonidet P40, 10 mM dithiothreitol). 
Isoelectric focusing was carried out at 15°C for 24,700 Vh, with 10 mM 
glutamic acid as anode buffer and 10 mM lysine as cathode buffer. After 
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Fig. 1. Dephosphorylation f 32P-phosphorylated VASP by different 
protein phosphatases a revealed by Coomassie blue staining (A) and 
autoradiography (B). Purified VASP was first phosphorylated in the 
presence of [7/-32P]ATP using the catalytic subunit of cAK. The kinase 
was subsequently inhibited by PKI, and aliquots of phosphorylated 
VASP were then incubated with 0.5/.tM of the respective phosphatase 
(PP1, PP2A, PP2B, PP2C) for 15 min or 30 min at 30°C. The phospho- 
rylation state of VASP was analyzed by SDS-PAGE and autoradiogra- 
phy. The positions of the 46 and 50 kDa forms of VASP are indicated. 
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Fig. 2. Time course of VASP dephosphorylation by PP2A analyzed by 
Coomassie blue staining (A) and 32p-autoradiography (B). After phos- 
phorylation of purified VASP (see section 2and Fig. 1), phosphorylated 
VASP was incubated with 0.3/zM PP2A at 30°C. At the time points 
indicated, aliquots were removed from the incubation mixture for the 
analysis of the VASP phosphorylation state by SDS-PAGE and 32p. 
autoradiography. The positions of the 46 and 50 kDa forms of VASP 
are indicated. 
focusing, gel strips were equilibrated twice for 15 min in a buffer 
containing 50 mM Tris-HC1 pH 6.8, 6 M urea, 30% (w/v) glycerol, 2% 
(w/v) SDS, 1% (w/v) dithiothreitol, 0.3% (w/v) Bromophenol b ue and 
then applied to an SDS slab gel. As internal pI standards, carbonic 
anhydrase II from bovine erythrocytes (pI 5.4; Sigma) and myoglobin 
from horse heart (pI 6.8 and 7.2; Sigma) were used. 
3. Results 
3.1. VASP is dephosphorylated by different protein serine/ 
threonine phosphatases in vitro 
When 3Zp-labeled VASP (phosphorylated by the catalytic 
subunit of the cAK as described in section 2) was incubated 
with each of four different protein phosphatases (PP), VASP 
dephosphorylation was demonstrated with PP2A, PP2B and 
PP2C, but not with PP 1 (Fig. 1). VASP dephosphorylation was 
detected by the shift of VASP from the 50 kDa to the 46 kDa 
species (analyzed by SDS-PAGE and Coomassie blue staining, 
Fig. 1A) and the concomitant loss of incorporated 32p (detected 
by autoradiography, Fig. 1B). The shift between the 50 kDa/46 
kDa VASP form is due to the phosphorylation/dephosphoryla- 
tion of VASP at Ser 157 [13]. Under the conditions tudied (Fig. 
1), PP2B and PP2C catalyzed partial VASP dephosphorylation, 
whereas VASP was completely dephosphorylated by PP2A but 
not at all by PP1. 
3.2. Protein phosphatase PP2A and PP2B dephosphorylate 
individual VASP phosphorylation sites with different 
selectivity 
Further investigations demonstrated significant differences 
between PP2A- and PP2B-catalyzed VASP dephosphorylation. 
Dephosphorylation f VASP by PP2A resulted in the decrease 
of the 32p-labeled, Coomassie blue-stained 50 kDa VASP form 
with the concomitant appearance of the 46 kDa VASP form 
and the transient appearance of 32p-label in the 46 kDa VASP 
species (Figs. 1 and 2). After a 30 min incubation with PP2A, 
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Fig. 3. Time course of VASP dephosphorylation by PP2B analyzed by 
Coomassie Blue staining (A) and 32p-autoradiography (B). 
Phosphorylated VASP (see section 2 and Fig. 1) was incubated with 0.3 
,uM PP2B. At the time points indicated, aliquots were removed and 
analyzed for the phosphorylation state of VASP by SDS-PAGE and 
32p-autoradiography. The positions of the 46 and 50 kDa forms of 
VASP are indicated. 
VASP had essentially lost all of its incorporated 32p and was 
completely shifted to the 46 kDa form. A 30 min incubation of 
phosphorylated VASP with PP2B converted about two thirds 
of the 50 kDa VASP to the 46 kDa form associated with the 
loss of most VASP-bound radioactivity (Figs. 1 and 4). How- 
ever, in contrast o the experiments with PP2A, a transient 
32p-labeled 46 kDa VASP form was not observed uring incu- 
bations with PP2B (Figs. 1, 3, and 4). The analysis of in vitro 
VASP dephosphorylation by two-dimensional gel electropho- 
resis (Fig. 4) indicated that extensively phosphorylated VASP 
consists of 2-3 spots (pI range 5.4-7) with the apparent molec- 
ular mass of 50 kDa. Incubation of phosphorylated VASP with 
PP2B shifts VASP both to the 46 kDa form and concomitantly 
to more basic (46 and 50 kDa) pI values without he transient 
appearance of a 32p-labeled 46 kDa form (Fig. 4). 
3.3. Effect of the protein phosphatase inhibitor okadaic acid on 
the state of VASP phosphorylation i  intact washed human 
platelets 
Okadaic acid (OA), a potent and specific inhibitor of PP1 
and PP2A in vitro and in intact cells [20], is a valuable tool for 
the classification and functional characterization of protein 
phosphatases [21]. Therefore, washed human platelets were in- 
cubated with various concentrations of OA for 40 min at 37 ° C, 
and platelet lysates were then analyzed for the state of VASP 
phosphorylation by two-dimensional gel electrophoresis and 
Western blotting. Treatment of human platelets with OA 
caused a concentration-dependent pI shift of VASP to more 
acidic values as well as a shift to the 50 kDa VASP form (Fig. 
5). Both effects are already noticeable at OA concentrations a
low as 50 nM (Fig. 5; other data not shown). Interestingly, the 
pattern of OA-induced changes in the state of VASP phospho- 
rylation (as analyzed by 2D gel electrophoresis and Western 
blotting) resembled those induced by the cAMP-elevating 
prostacyclin analogue Iloprost and those induced by the mem- 
brane permeable cAMP analogue Sp-5,6-DCI-cBiMPS (Fig. 5). 
In unstimulated washed human platelets, VASP was present 
primarily as 46 kDa species of 2-3 spots. Although the precise 
pI of the most basic spot has not been determined, it ap- 
proaches extremely basic values which is consistent with a pI 
of 9.55 calculated from the VASP amino acid sequence [14]. 
Iloprost, Sp-5,6-DCI-cBiMPS and OA shifted all or most of 
VASP to the 50 kDa form, with the extensively phosphorylated 
VASP comprising 2-3 spots at pI 5.4-7 (Fig. 5, Iloprost). 
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Fig. 4. Two-dimensional gel electrophoresis howing the selective dephosphorylation of VASP phosphorylation sites by PP2B. Phosphorylated VASP 
was incubated with PP2B for 15 min and 45 min. Aliquots of phosphorylated VASP were removed before and after incubation with PP2B and analyzed 
by two-dimensional gel electrophoresis followed by 32p-autoradiography (right panel) and Western blotting with an ECL detection system (left panel). 
The positions of the 46 and 50 kDa VASP forms are indicated. The pI of internal pI standards are marked with points, from left to right pI 5.4, 
pI 6.8, pI 7.2. 
K. Abel et al./FEBS Letters 370 (1995) 184-188 187 
wlo 
Okadaic acid 
50nM 
Okadaic acid 
lOOnM 
Okadaic acid 
'*"- 46 kDa ---* 
,=--- 50 kDa - - *  
46 kDa ---* 
50 kDa 
46 kDa ---* 
/ Control 
Sp-5,6-DCI -  
cB iMPS 
Iloprost 
Fig. 5. Effects of okadaic acid on the VASP phosphorylation state in intact human platelets in comparison to the effects of Iloprost and Sp-5,6-DC1- 
cBiMPS. Washed platelets were incubated without (w/o) or with okadaic acid (50 nM or 100 nM for 40 min), or with Sp-5,6-DCI-cBiMPS (0.2 mM 
for 30 min) or Iloprost (5 nM for 5 min), respectively. The phosphorylation state of VASP was then analyzed by two-dimensional gel electrophoresis 
followed by Western blotting using anti-VASP antibodies. The positions of the 46 and 50 kDa VASP forms are indicated. The pI of internal pI 
standards are marked with points, from left to right pI 5.4, pI 6.8, pl 7.2. 
4. Discussion 
Phosphorylation of VASE an established cAK and cGK 
substrate, has been extensively examined in vitro and in living 
cells [4-8,13]. In human platelets, reversibility of the phospho- 
rylation-induced shift of VASP from the 46 to the 50 kDa form 
(due to VASP phosphorylation at Ser 157) has been reported to 
occur within a few minutes after the removal of pharmacologi- 
cal or physiological stimuli [8,31]. These data already suggested 
that protein phosphatases, in addition to protein kinases, play 
a major role in regulating the state of VASP phosphorylation 
in intact cells. However, the protein phosphatases involved 
have not been studied so far. Our present data demonstrate hat 
phosphorylated VASP is a substrate of protein phosphatase 
PP2A, PP2B and PP2C in vitro and a substrate of an OA- 
sensitive phosphatase (most likely PP2A) in intact human plate- 
lets. Furthermore, the phosphatases studied dephosphorylate 
individual VASP phosphorylation sites with different selectiv- 
ity. The transient appearance of a 32p-labeled 46 kDa VASP 
species during PP2A-catalyzed ephosphorylation i dicates 
that PP2A dephosphorylates he phosphorylation site responsi- 
ble for the mobility shift in SDS-PAGE (Ser 157) somewhat faster 
or at least with a similar rate as compared with the 
dephosphorylation f the two other VASP phosphorylation 
sites (Ser 239, Thr278). In contrast, the absence of a transiently 
labeled 46 kDa VASP species during the PP2B- and PP2C- 
catalyzed VASP dephosphorylation indicates that PP2B (and 
PP2C as well) completely dephosphorylates other phosphoryla- 
tion sites (Ser 239, Thr 278) prior to dephosphorylation f Ser 157. 
The phosphatases PP1, PP2A and PP2C are known to have a 
broad and overlapping substrate specificity while PP2B is the 
most specific protein phosphatase [32,33]. The specificity of 
PP2B towards its substrates does not primarily depend on a 
specific consensus equence but instead is mostly determined 
by higher-order structural features [32,34,35]. Nevertheless, in
studies with phosphopeptides it has been shown [35] that an 
arginine at position -3 of the phosphorylation site is required 
for dephosphorylation by PP2B. This criterion is fulfilled by all 
three VASP phosphorylation sites (IERRVS157NAGG, 
KLRKVSZ39KQEE, RRRKAT278QVGE) [14]. Furthermore, 
there is no acidic residue adjacent o the C-terminal side of 
Ser ~57 (see above) which has been characterized as a strong 
negative determinant. Therefore, the preferential PP2B-cata- 
lyzed dephosphorylation f VASP Ser239/Thr278 (as compared 
to VASP Ser 157) may also be due to the higher-order structure 
of VASE 
Another goal of our study was the possible identification of 
protein phosphatase(s) involved in VASP dephosphorylation n 
intact cells. Incubation of intact human platelets with OA 
caused the accumulation of phosphorylated VASP forms. 
These data indicate an equilibrium between phosphorylation 
(protein kinases) and dephosphorylation (protein 
phosphatases) in resting platelets which can be shifted by phos- 
phatase inhibitors in favor of the phosphorylated products. The 
OA-induced accumulation ofphosphorylated VASP forms sug- 
gests OA-sensitive protein phosphatases PP1 and/or PP2A [20] 
as the major phosphatases responsible for VASP 
dephosphorylation in intact human platelets. In vitro, a distinc- 
tion between PP1 and PP2A can be made by the OA concentra- 
tion needed for protein phosphatase inhibition. Whereas in 
vitro PP2A is completely inhibited by 1 nM OA, PP1 is unaf- 
fected by this concentration [26]. However, it is difficult to 
distinguish PP1 and PP2A in intact cell preparations by the use 
of OA alone because (due to the high intracellular concentra- 
tion of protein phosphatases which may range from 0.1-1 pM 
[26,36]) higher OA concentrations may be required. In human 
platelets, the major serine/threonine protein phosphatases de- 
tected are PP1, PP2A and PP2B [15,16,18]. This information, 
our experiments with purified protein phosphatases (Figs. 1-4) 
and the results obtained with OA (Fig. 5) therefore suggest that 
the principal protein phosphatase responsible for VASP 
dephosphorylation in intact human platelets is PP2A. 
OA-induced accumulation of phosphorylated VASP resem- 
bled that induced by platelet cAK activators (e.g. Iloprost and 
Sp-5,6-DCI-cBiMPS) as shown in Fig. 5. These results together 
with the observation that OA preincubation [15,22-25] as well 
as cAK or cGK stimulation [2,3,37,38] inhibit thrombin-in- 
duced platelet activation and associated events uch as aggrega- 
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tion, Ca 2+ mobilization and serotonin release suggest hat the 
inhibitory OA effects on intact human platelets are, at least in 
part, due to elevated phosphorylation f cAK substrates. 
Repeatedly, the phosphorylation f an unidentified 50 kDa 
protein after platelet incubation with OA has been reported 
[15,23,24]. Based on the comparison of two-dimensional gel 
electrophoresis, effects of cAMP-elevating agents uch as fors- 
kolin or prostaglandin El and associated functional effects 
[15,23] our present data suggest hat the 50 kDa unidentified 
phosphoprotein of these previous studies is VASE Although 
VASP phosphorylation is a very sensitive marker of OA action 
in human platelets we certainly do not want to rule out that 
other phosphoproteins (including other cAK substrates) are 
important targets for the effects of protein phosphatase inhib- 
itors. This appears to be especially relevant with respect o 
calyculin and tautomycin which, at low concentrations, selec- 
tively inhibited thrombin-induced Ca2+ influx rather than Ca 2+ 
mobilization from intracellular stores [22]. 
In conclusion, our present results demonstrate hat the three 
established VASP phosphorylation sites are selectively used not 
only as protein kinase substrates [13] but also as protein phos- 
phatase substrates. In intact human platelets, VASP phospho- 
rylation is not only increased by cAK/cGK activation but also 
by protein phosphatase inhibition which most likely involves 
PP2A. These data suggest a tight balance between VASP phos- 
phorylation and dephosphorylation which, at least in human 
platelets, can be rapidly altered by the regulation of either 
protein kinases [29] or protein phosphatases (this study). Con- 
sidering the potentially important role of VASP as link between 
signal transduction pathways and the regulation of cell motility 
[11,12] our present data should be helpful for future attempts 
to define the regulatory role of the various VASP phosphoryl- 
ation sites in intact cells at the molecular level. 
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